122 filings
Page 3 of 7
8-K
14517oybuerh5
10 Nov 22
Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights
4:13pm
8-K
5frrpwal1cz1ke
24 Oct 22
Invivyd Announces the Appointment of Christine Lindenboom to Board of Directors
4:30pm
8-K
zaxdi1av1ej63e
13 Oct 22
Invivyd Appoints Fred Driscoll as Interim Chief Financial Officer and Announces Resource Reallocation to Maximize Integrated Discovery
4:16pm
EFFECT
dfq9a8
6 Oct 22
Notice of effectiveness
12:15am
CORRESP
q1a0e9w
3 Oct 22
Correspondence with SEC
12:00am
UPLOAD
5n67 1bky
30 Sep 22
Letter from SEC
12:00am
S-3
q8aenk6t0y y5585xlws
28 Sep 22
Shelf registration
5:08pm
8-K
sicru5nfik4d
13 Sep 22
Amendments to Articles of Incorporation or Bylaws
12:00am
8-K
a4f1ut ffsh
12 Sep 22
Adagio Therapeutics Announces Corporate Name Change to Invivyd
7:46am
8-K
q6w9w83u8s
15 Aug 22
Adagio Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
7:22am
8-K
1f3bnl854gisgrk76
5 Jul 22
Adagio Announces Results of Annual Meeting of Stockholders and Evolution of the Board of Directors
4:41pm
8-K
8fbu724gle19gzk 7n
30 Jun 22
Departure of Directors or Certain Officers
4:30pm
8-K
tkofgmm
22 Jun 22
Submission of Matters to a Vote of Security Holders
5:18pm
DEFA14C
kxb6qhm9uonc5dou2bmo
21 Jun 22
Additional information
5:19pm
8-K
acyqkw4a9td4pzh
21 Jun 22
Departure of Directors or Certain Officers
5:17pm
DFAN14A
p82163iau
3 Jun 22
Additional proxy materials by non-management
9:51pm
DEFC14C
bkp417
2 Jun 22
Information statement in contested solicitation
4:24pm
PRER14C
neivn9dq703j
31 May 22
Preliminary revised information
5:09pm
CORRESP
lt7uvtaonc9512ca
31 May 22
Correspondence with SEC
12:00am